1 January 2022 in Journal of Korean Medical Science
Jang YR, et al. J Korean Med Sci. 2022 Jul;37(27):e224. https://doi.org/10.3346/jkms.2022.37.e224
31 August 2022 in Osong Public Health and Research Perspectives
Objectives: Monkeypox outbreaks in nonendemic countries have been reported since early May 2022. The first case of monkeypox in the Republic of Korea was confirmed in a patient who traveled to Europe in June 2022, and an attempt was made to isolate and identify the monkeypox virus (MPXV) from the patient’s specimens.Methods: Clinical specimens from the patient were inoculated in Vero E6 cells. The isolated virus was identified as MPXV by the observation of cytopathic effects on Vero E6 cells, transmission electron microscopy, conventional polymerase chain reaction(PCR), and sequencing of PCR products.Results: Cytopathic effects were observed in Vero E6 cells that were inoculated with skin lesion swab eluates. After multiple passages from the primary culture, orthopoxvirus morphology was observed using transmission electron microscopy. In addition, both MPXV-specific (F3L and ATI) and orthopoxvirus-specific genes (A39R, B2R, and HA) were confirmed by conventional PCR and Sanger sequencing.Conclusion: These results indicate the successful isolation and identification of MPXV from the first patient in the Republic of Korea. The isolated virus was named MPXV-ROK-P1-2022.
31 October 2020 in Osong Public Health and Research Perspectives
The Korea Centers for Disease Control and Prevention has published "A Guideline for Unknown Disease Outbreaks (UDO)." The aim of this report was to introduce tabletop exercises (TTX) to prepare
1 January 2024 in Journal of Korean Medical Science
Choi CH, et al. J Korean Med Sci. 2024 May;39(18):e165. https://doi.org/10.3346/jkms.2024.39.e165
1 April 2008 in Biochemical and Biophysical Research Communications
13 May 2026 in Journal of Clinical Microbiology
Lassa fever is a high-risk viral disease endemic to West Africa for which rapid and reliable diagnosis is essential for outbreak control. Here, we describe the development of a lateral flow-based rapid diagnostic test (RDT) targeting the Lassa virus nucleoprotein using newly generated monoclonal antibody pairs. The analytical performance of the assay was evaluated using human serum and plasma specimens as well as inactivated Lassa virus strains and compared with a commercially available antigen test. The final RDT (Pair 2; 1P-44-7/9B-28) demonstrated high analytical sensitivity and 100% specificity across 60 human samples and detected multiple genetically diverse Lassa virus strains, with lineage-dependent differences in analytical sensitivity. In direct analytical comparisons using recombinant antigen, the assay was approximately 64-fold more sensitive than the ReLASV Pan-Lassa Antigen Rapid Test. The RDT provides a rapid visual readout, remains stable at ambient temperatures, and is suitable for decentralized testing workflows, features aligned with key aspects of the World Health Organization (WHO) REASSURED framework. These results indicate that the developed RDT offers a robust and broadly reactive platform for Lassa virus antigen detection and has potential utility for surveillance and outbreak response in resource-limited settings. IMPORTANCE: Lassa fever remains a significant public health concern in West Africa, where diagnostic capacity is often limited in endemic regions. This study describes the development of a broad-lineage Lassa virus rapid diagnostic test informed by the World Health Organization (WHO) REASSURED framework. The assay demonstrates high analytical sensitivity and broad lineage coverage in a field-deployable format, supporting its potential utility for early case detection and decentralized surveillance in endemic settings.